In cohorts treated primarily by surgical resection and adjuvant therapy, median PFS for IDH1/2 mutant grade 2 and 3 gliomas ranged from 46.8 to 78.0 months [18,30,38,39]. The gene discussed is IDH1; the disease is central nervous system cancer.